Cervical Carcinoma Clinical Trial
Official title:
Can Text Reminders Improve Uptake of Cervical Screening? A RCT.
NCT number | NCT02363088 |
Other study ID # | 14IC2120 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 2015 |
Est. completion date | February 2016 |
Verified date | October 2018 |
Source | Imperial College Healthcare NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cervical cancer is the most common cancer in women under 35 years and is a major public
health concern. Fortunately, the natural history of this malignancy can be beneficially
improved through cytological screening. However, the success of screening programmes depends
on their ability to attract the "at risk" population, as well as the analytical sensitivity
and specificity of the screening test. In the UK, screening consistently falls short of the
80% national target and recent evidence shows uptake is decreasing, in part due to the
introduction of HPV vaccination programmes. In the under 30s London population, average
coverage only reached 50% in 2013. Given this information, the cervical screening programme
is under increasing pressure to improve uptake, and need an evidence based intervention.
We aim to improve the uptake of cervical screening using SMS messaging through a randomised
controlled trial. The trail will evaluate both the prevalent and incident rounds of screening
and within the intervention group, analyse how the content of text reminders influences their
effectiveness. Specifically we will evaluate a) neutral b) messenger c) social norms d)
framed gain/loss reminders. Unlike our previous trial, this SMS reminder will encourage the
booking of an appointment which has never been tested, rather than simply reminding women to
attend. All women being invited for cervical screening, registered at participating GPs
within Hillingdon will be eligible to participate. Women will also be provided with a 2 week
window during which they can opt out of the research. Given the sample sizes we predict the
trial will take 9 months.
Status | Completed |
Enrollment | 14597 |
Est. completion date | February 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 24 Years to 64 Years |
Eligibility |
Inclusion Criteria: Women aged 24-64 years being invited for cervical screening during the course of the study. Women included in the study will be registered with a GP Practice that has agreed to participate in the trial. Exclusion Criteria: Patients who opt-out, Patients who have had a hysterectomy, Patients who have informed GP practices of preference to not be screened, Patients Cervical cancer |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Department of Surgery and Cancer, St Mary's Campus, Praed Street, Imperial College London | London |
Lead Sponsor | Collaborator |
---|---|
Sarah Huf |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intention to treat analysis | Analysis of the rate of cervical screening by trial arm at the end of the screening round (32 weeks) | 13 months | |
Secondary | Attendance by age (control vs interventions) | Attendance within different groups by trial arm | 13 months | |
Secondary | Attendance by level of deprivation (control vs interventions) | Attendance within groups of different levels of deprivation (using IMD) by trial arm | 13 month | |
Secondary | Per protocol analysis using SMS delivery status data to compared the rate of cervical screening in women who receive the SMS at the end of the screening round (32 weeks from screening invitation) | Analysis of the rate of cervical screening by trial arm using SMS delivery status data to compared the rate of cervical screening in women who receive the SMS at the end of the screening round (32 weeks from screening invitation) | 13 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05458869 -
Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
|
||
Not yet recruiting |
NCT04483557 -
Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility
|
Phase 2 | |
Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04452526 -
I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination
|
N/A | |
Active, not recruiting |
NCT04443296 -
Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma
|
Phase 1 | |
Recruiting |
NCT05180851 -
Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study
|
Early Phase 1 | |
Withdrawn |
NCT03220009 -
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
|
Phase 2 | |
Completed |
NCT02460237 -
HPV Self-Test Intervention in Ohio Appalachia
|
N/A | |
Terminated |
NCT00924066 -
Ixabepilone to Treat Cervical Cancer
|
Phase 2 | |
Completed |
NCT04208724 -
Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization
|
N/A | |
Completed |
NCT03307044 -
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
|
N/A | |
Recruiting |
NCT05139368 -
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
|
N/A | |
Completed |
NCT03180294 -
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
|
Phase 2 | |
Recruiting |
NCT05366478 -
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03849469 -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT03345784 -
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
|
Phase 1 | |
Completed |
NCT02523365 -
HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Cervical Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT03372720 -
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03752398 -
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
|
Phase 1 | |
Active, not recruiting |
NCT00867464 -
Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
|